Founded in December 2, Wuxi PharmaTech New Drug Development Co., Ltd. is the world's leading outsourcing service company for pharmaceutical, biotechnology and medical device research and development, with operating entities in both China and the United States. On August 9th, 27, the parent company Wuxi Wuxi WuXi PharmaTech (Cayman) Co., Ltd. was officially listed on the new york Stock Exchange, and its american depository receipts trading code was WX. As a research-oriented and customer-centered company, Wuxi PharmaTech provides a series of comprehensive laboratory research and development, research and production, biological agent testing and production services to pharmaceutical companies, biotechnology companies and medical device companies around the world, and the service scope runs through the whole process of pharmaceutical and medical device research and development. WuXi PharmaTech's service aims to help its global partners shorten the research and development cycle of drugs and medical devices and reduce research and development costs. Our services are divided into two parts: laboratory services, including synthetic chemistry, biological detection, toxicology, preclinical drug development, analytical services, biopharmaceuticals and medical device testing, and other related contract research and development services. Production services, pharmaceutical intermediates, APIs production services, cell banking services, cell therapy and cGMP production of products based on compounds and tissues. The company's top management team consists of a group of doctors and MBA students with rich experience in pharmaceutical, biotechnology and medical device research and development. Our senior management team * * * has more than 2 authorized and pending patent achievements, more than 8 high-level academic papers, and an average of 15 years of experience in international first-class pharmaceutical, biopharmaceutical and medical device companies. The total number of employees in the company has exceeded 3,7. The company's facilities in China include a 59,m2 R&D center in Shanghai Waigaoqiao Free Trade Zone, a 2,4m2 process R&D and cGMP production base in Jinshan District, Shanghai, a 33,m2 second-phase expansion project, a 12,m2 R&D center mainly providing chemical services for drug research and development in Tianjin, and a 3,m2 Suzhou Toxicology Center. The company's facilities in the United States have all been approved by the US Food and Drug Administration, including 7,7 square meters R&D and production center in St. Paul, Minnesota, 4,6 square meters testing center in Atlanta, Georgia, and 7, square meters R&D, testing and production center in Philadelphia, Pennsylvania. Interested parties please log on to the company website /hrtest/Default2.aspx to fill in your resume. Company website: Address: No.288, Fute Middle Road, Waigaoqiao Free Trade Zone, Shanghai Postal Code: 2131 Contact: hr@wuxiapptec.com E-mail: hr@wuxiapptec.com